CN101272770A - Method for stabilising pharmaceutical administration forms that contain micro-organisms - Google Patents
Method for stabilising pharmaceutical administration forms that contain micro-organisms Download PDFInfo
- Publication number
- CN101272770A CN101272770A CNA2006800355746A CN200680035574A CN101272770A CN 101272770 A CN101272770 A CN 101272770A CN A2006800355746 A CNA2006800355746 A CN A2006800355746A CN 200680035574 A CN200680035574 A CN 200680035574A CN 101272770 A CN101272770 A CN 101272770A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- packing
- administration form
- microorganism
- solid drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 32
- 230000003019 stabilising effect Effects 0.000 title abstract description 3
- 239000007787 solid Substances 0.000 claims abstract description 46
- 238000012856 packing Methods 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims description 49
- 229940079593 drug Drugs 0.000 claims description 43
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 239000002250 absorbent Substances 0.000 claims description 22
- 230000002745 absorbent Effects 0.000 claims description 22
- 239000000654 additive Substances 0.000 claims description 17
- 239000003826 tablet Substances 0.000 claims description 16
- 235000016709 nutrition Nutrition 0.000 claims description 14
- 230000035764 nutrition Effects 0.000 claims description 14
- 239000006041 probiotic Substances 0.000 claims description 14
- 230000000529 probiotic effect Effects 0.000 claims description 13
- 235000018291 probiotics Nutrition 0.000 claims description 13
- 239000002274 desiccant Substances 0.000 claims description 12
- 241000186660 Lactobacillus Species 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 235000010755 mineral Nutrition 0.000 claims description 7
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 6
- 241001608472 Bifidobacterium longum Species 0.000 claims description 6
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 5
- 235000013325 dietary fiber Nutrition 0.000 claims description 5
- 239000008298 dragée Substances 0.000 claims description 5
- 239000011573 trace mineral Substances 0.000 claims description 5
- 235000013619 trace mineral Nutrition 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 244000199866 Lactobacillus casei Species 0.000 claims description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 4
- 244000057717 Streptococcus lactis Species 0.000 claims description 4
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 4
- 229940017800 lactobacillus casei Drugs 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 3
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 3
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 3
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 3
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 3
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 235000011868 grain product Nutrition 0.000 claims description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 3
- 239000002808 molecular sieve Substances 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical group [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 9
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 27
- 241000894006 Bacteria Species 0.000 description 15
- 239000000203 mixture Substances 0.000 description 12
- -1 piller Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000007902 hard capsule Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000001913 cellulose Chemical class 0.000 description 4
- 229920002678 cellulose Chemical class 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920002774 Maltodextrin Chemical class 0.000 description 2
- 239000005913 Maltodextrin Chemical class 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229930006000 Sucrose Chemical class 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229960002181 saccharomyces boulardii Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 239000005720 sucrose Chemical class 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 229940120293 vaginal suppository Drugs 0.000 description 2
- 239000006216 vaginal suppository Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Chemical class OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- 239000005995 Aluminium silicate Chemical class 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical class OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229920005648 ethylene methacrylic acid copolymer Polymers 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical class O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention relates to a method for stabilising solid pharmaceutical administration forms, which contain at least one genus of micro-organisms, in addition to packaging comprising a packing material. The invention also relates to a solid pharmaceutical administration form, which contains at least one genus of micro-organisms.
Description
The present invention relates to be used for the stable method that comprises the solid drugs administration form of at least a microorganism, and contain the bag of packing and containing the solid drugs administration form of at least a microorganism.
Microorganism often is present in the solid drugs administration form, and the latter can be used by oral, vagina or anus.Therefore, for example, probiotic micro-organisms uses in Orally administered medicine to improve or to eliminate because the symptom that multilated or destructive intestinal flora cause.Further embodiment is the vaginal suppository that comprises culture of microorganism, bacillus acidophilus (Lactobacillus acidophilus) bacterial strain for example, it uses in order to stablize vaginal flora, and make urinary tract infection recurrence frequency reduce that (people such as Reid G.: three days antimicrobial therapy of lactobacillus vaginal suppository is to the influence of urinary tract infection recurrence, Clin Ther1992; 14:11-6).
In order to make preparation effective, the microorganism in the preparation exists and can breed with the form of living when using is necessary.Therefore target with ensuing lay up period during the preparation of the pharmaceutical administration forms that comprises microorganism is the activation of microorganism of keeping existence as much as possible.
Being used to prepare and storing the method that comprises microbial medicine is that prior art is known.Therefore, for example, EP0131114A1 has described the lactobacillus preparation that in addition is dried by with bacterial suspension after powdery or particle carrier material.After preparation, said preparation is introduced in the packing of protective atmosphere of anaerobic so that keep activation of microorganism at lay up period.
DE19819475 has described the drying means that is used for culture of microorganism, and it has claimed to improve the long term storage stability of culture.At target mass be water activity (a in the material that is dried
w) less than 0.15.In order to realize this target mass, the material that is dried is must be in fluidized-bed process dry, and/or must add and have a
wThe adjuvant of value≤0.01.
At least a because of in the following reason, the known method that is used to improve the prior art of bin stability is unsafty:
1. method is very complicated technically;
2. too high to the active requirement of the water of adjuvant;
3. the bin stability of administration form is too low;
4. method is commercial too expensive;
5. method causes heat damage to culture of microorganism and/or adjuvant and reactive compound.
The purpose of this invention is to provide the method that no longer includes the described shortcoming of prior art.Especially, this method implements simple and spends not high, allow to use the active adjuvant of any water, can not cause microorganism and comprise the thermal strain of its administration form, and have the effect of promptly taking basic maintenance microbial activity at the whole lay up period of medicine until the patient.
Make us uncannily, this target is introduced into absorbent and at least a passage to form agent is to embed in the packing to the small part of its inner wall area to realize by comprising solid administration form according to the microorganism of prior art for preparing.Therefore the present invention relates to and is used for the stable method that comprises the solid drugs administration form of at least a culture of microorganism, it is characterized in that the solid drugs administration form is introduced in absorbent and at least a passage and forms in the packing of subregion at least that agent embeds its inwall.After being introduced into the solid drugs administration form in this packing, the latter for example seals with the form of lid.The inwall meaning is the inner surface of package wall, i.e. the surface of package that contacts with the solid drugs administration form that exists wherein.
This method can be used for all and is the solid-state physics state and will be used for for example oral, anus or all solids pharmaceutical administration forms of vaginal application in room temperature.All are removing solid drugs administration forms of directly using after the packing such as for example, but tablet, dragee, hard capsule, granule, piller, powder, piller, suppository, and before using, can be converted into administration form such as, for example, dried juice, the powder type that for example must be transformed into solution before using includes interior.Pharmaceutical administration forms is tablet, dragee, hard capsule, grain products, suppository, pilule or powder preferably.Hard capsule has the shell that does not add plasticizer, can be divided into the upper and lower part, and is made up of for example gelatin or starch.
The pharmaceutical administration forms that uses in the context meaning is the term that becomes known for the various technology administration forms that the mankind or animal use, the expression of pharmaceutical administration forms is therefore irrelevant with discrete statutory status, and never be limited to medicine, composition, may there be various materials in it, such as, for example medicine, dietary supplement and/or functional components.The example that is used for the pharmaceutical administration forms of the object of the invention can be the form of medicine and dietary supplement.
The microorganism that can exist is the microorganism that usually himself is present in healthy human body or animal health or healthy, damage or ill human body or animal health is had the health promotion effect.The microorganism that can exist for example is, antibacterial, fungus and/or yeast.
Preferred microorganism is the yeast of living, such as, for example saccharomyces boulardii (Saccharomycesboulardii) and/or antibacterial, special preferred bacterium, it very particularly preferably is probiotic bacteria, such as for example, lactobacillus (lactobacilli), bacillus bifidus (bifidobacteria) and/or streptococcus (streptococci).This paper particularly preferably provides following bacterial strain: lactobacillus casei (Lactobacilluscasei), the bacillus acidophilus, Lactobacillus reuteri (Lactobacillus reuteri), bifidus (Lactobacillus bifidum), Lactobacillus gasseri (Lactobacillus gasseri), Lactobacillus plantarum (Lactobacillus plantarum), Yue Hanxunshi lactobacillus (Lactobacillus johnsonii), lactobacillus rhamnosus (Lactobacillus rhamnosus), Lactobacillus fermenti (Lactobacillusfermentum), Lactobacillus paracasei (Lactobacillus paracasei), Lactobacillus crispatus (Lactobacillus crispatus), bifidobacterium longum (Bifidobakterium longum), bifidobacterium bifidum (Bifidobakterium bifidum), bifidobacterium longum, breast bifidus bacillus (Bifidobakterium lactis), short bifidus bacillus (Bifidobakterium brevis), animal bifidus bacillus (Bifidobakterium animals), bifidobacterium adolescentis (Bifidobakteriumadolescentis), bifidobacterium infantis (Bifidobakterium infantis), streptococcus thermophilus (Bifidobakterium thermophilus) and/or lactococcus lactis (Lactococcus lactis).
The packing that is fit to is a polymer container.Absorbent and passage form agent and can together exist, no matter directly maybe can paste one deck in the inwall of polymer formation container on the inwall of polymer container.Absorbent and passage form agent can similarly embed inlay, and it is incorporated in the packing as inert layer, so that Bao Zhuan part inwall is serving as a contrast with it at least.
For the purposes of the present invention, container is the single dose container, such as for example blister pouch, with multi-dose container, and such as for example, spiral cover container or tablet pipe.
The polymer that can be used as the mixture of absorbent and passage formation agent is, especially, thermoplastic is such as for example, polyolefin is such as polyethylene and/or polypropylene, polyisoprene, polybutadiene, polybutene, polysiloxanes, polyamide, ethylene-vinyl acetate copolymer, ethylene-methacrylic acid copolymer, polystyrene, polyester, poly-anhydride, the polyacrylate nitrile, polysulfonates, polyesteramide, polyacrylate, propylene-maleic anhydride, polyvinyl-maleic anhydride, polyethylene-urethanes, polyethylene-ethyl vinyl alcohol, polyethylene-nylon and/or polyurethane.The surface provides these walls with absorbent and passage formation agent to have the gross weight that forms agent and absorbent based on polymeric blends, passage within it, and polymer content is 10-90% by weight.
The absorbent that exists is any type of desiccant basically, i.e. the bonding agent of bound moisture.Can consider such three class desiccant:
The first kind comprises the chemical substance that forms hydrate with water.The example of such chemical substance is an anhydrous salt, tends to absorb moisture or dampness and form stable hydrate in this process.Moisture is combined, and can prevent its release by chemical reaction.
The second class desiccant comprises reactive materials.This class material and water or dampness reaction form novel substance.The new material that forms is stable at low temperatures usually, and needing to consume high energy could reverse.This type of desiccant be mainly used in dry solvent and in polymer as the water adsorbing material, himself must keep the moisture reducing condition.
The 3rd class desiccant is by the physical absorption bound moisture.Desiccant comprises the granule with the fine, soft fur tubule that can absorb moisture.Aperture capillaceous and density thereof in this paper desiccant have determined its absorption characteristic.The embodiment of the desiccant of this type is molecular sieve, silica gel, some synthetic polymer such as for example, is used for those and starch of baby diaper.The 3rd class desiccant preferably is present in the packing because they are inert basically and are water-insoluble.It here is particularly preferred having the molecular sieve in 3 to 15 dust apertures and/or the silica gel in 24 dust apertures is arranged.
It is hydroaropic substance that the passage that can consider forms agent, such as for example, and polymeric alcohol, ethyl vinyl alcohol, glycerol, polyvinyl alcohol, polyvinylpyrrolidone, vinylpyrrolidone, N-Methyl pyrrolidone, polysaccharide, saccharide and/or sugar alcohol.Preferred polymeric alcohol is Polyethylene Glycol and/or polypropylene glycol.Spendable sugar is for example glucose, mannose, galactose and/or fructose.The sugar alcohol that is fit to for example is, mannitol, sorbitol, hexitol, galactitol, xylitol, ribitol and/or erythritol.Polysaccharide is meant for example dextrin and/or hydroxylating starch.
Provide in inwall with absorbent and passage and form agent, passage formation agent can have the ratio based on the 10-40% by weight of the mixture total weight of polymer, passage formation agent and absorbent.
Absorbent and passage form in the inwall that agent is embedded into the subregion of container or Zone Full.The part meaning in zone be form inwall container overall area comprise absorbent and passage forms agent to small part.In the whole zone meaning is that the whole zone that forms inwall comprises absorbent and passage formation agent.According to preferential embodiment, absorbent and passage form agent and are present at least 10%, preferably at least 50%, particularly preferably at least 90% inwall based on the total inner surface of container at least.
Comprise absorbent and passage form agent polymer and with the container of its preparation, but container the method according to this invention is as packing, be that prior art is known and for example be described in, among WO97/32663A1, EP1000873A2 and WO03/086900A1, EP1421991A1, the WO00/76879.The packing that can be used for the inventive method is commercially available, and can be for example by Capitol Specialty PlasticsInc., 2039 McMilan Street Auburn, Alabama, USA, its commodity are called Activ-Vial, or by S ü d Chemie Ostenrieder Str.15,85368 Moosburg, Germany provides with trade name 2AP Multipolymer.
The method according to this invention can make the supply of solid drugs administration form stable, that comprise at least a culture of microorganism not expensive.These can use not expensive raw material preparing, and these not expensive raw materials according to prior art since its high water activity value or changing into essential other drying steps can not be as parent material before or after the pharmaceutical administration forms.
Make us uncannily, the method according to this invention also can provide the gone on the market product of the solid drugs administration form that comprises at least a culture of microorganism, before this because its inadequate bin stability of prior art is unsuitable for listing.After administration form was transferred in the packing, water was removed from administration form by the absorbent that exists in the packing inwall constantly for a long time.The removal of moisture occurs under the condition of large area region and gentleness, and therefore can make the solid drugs administration form stable at its lay up period.
The stabilisation that comprises the solid drugs administration form of at least a culture of microorganism, use and the method suitable according to the present invention, even may be difficult for realizing at the preparation after drying, because prolonging the reason of drying time from time and cost aspect under the comparatively gentle condition can not implement, and particularly there is microorganism wherein in the dry destruction that causes pharmaceutical administration forms of heating up.
The static stabilization of the method according to this invention is based on the influence of packing to the solid drugs administration form, and therefore it can provide the form of stable storage.Realization needs solid drugs administration form according to effect of the present invention is present in this packing, and promptly administration form and packing one coexist in the sack.
Therefore the present invention also relates to and comprises at least a passage and form agent and be embedded into the packing of its inwall at subregion and at least a absorbent at least, and comprises the solid drugs administration form of at least a culture of microorganism, as above hereinafter described in.
Sack can comprise any solid drugs administration form that contains at least a culture of microorganism.According to the preferred embodiment of the invention, sack comprises, and as the solid drugs administration form, is for Orally administered solid drugs administration form, particularly tablet, dragee, hard capsule, grain products, suppository or powder.The pharmaceutical administration forms that is present in the bag can comprise any amount of for purpose microorganism separately.The solid drugs administration form that is present in the bag preferably comprises 10
3To 10
12, particularly preferably 10
5To 10
11, and most preferably 10
7To 10
10Probiotic microorganisms.
After Orally administered, probiotic microorganisms its health promotion act on human or animal's small intestinal realize before by inactivation widely between gastric phase.In order to ensure probiotic microorganisms in the abundant high activity of human body and animal small intestinal; therefore the Peroral solid dosage form pharmaceutical administration forms that is present in the bag is preferably provided with the clothing layer; this clothing layer protection microorganism is dissolved in small intestinal then by non-inactivation between gastric phase, so that microorganism obtains discharging at small intestinal.Suitable clothing layer is all systems, preferred pH-control, such as for example, anti-gastric juice clothing layer, promptly be used in the acidic gastric juice insoluble and be the clothing layer of soluble material preparation in (more alkaline) small intestinal, or the clothing layer of time control, promptly Orally administered give humans and animals after the dissolving of preset time Duan Houyi layer, irrelevant with the pH of environment, set this time period to make it arrive the time of small intestinal target site from preparation digestion to it corresponding to administration form.Perhaps, microorganism itself but not whole solid drugs administration form also can be provided to the protective clothing layer.
According to embodiment preferred more, be present in the solid drugs administration form in the bag, if particularly it is used for Orally administeredly, except that probiotic microorganisms, also comprise the nutrition associated additives.Preferably little element, mineral, trace element, dietary fiber, enzyme, plant extract, protein, the sugar and/or fatty of giving birth to of the additive that the nutrition that can exist is relevant.If Orally administered form comprises the relevant additive of nutrition that its digestion early begins under one's belt, such as for example, protein, importantly these nutrition associated additives are at least by halves by clothing layer coating.
The oral drugs administration form and the other nutrition associated additives that comprise probiotic microorganisms are known from EP931543A1.As described herein, comprising probiotic microorganisms is unsettled together with the preparation of described nutrition associated additives.For the Orally administered form that comprises probiotic microorganisms and nutrition associated additives is provided, can imagines probiotic microorganisms and nutrition associated additives and be distributed in apart from each other in the different layers in the multilayer tablet.For the stability that realizes, the layer that comprises microorganism should have low-down water content, and it can be by very carefully dried microorganism cultures and carrier mass are realized their mixing again.But the precondition of the drying of microorganism and carrier mass and multilayer tablet preparation is complicated aspect equipment and is time-consuming, and causes high production cost on the whole.
Make us uncannily, found can stable storage form the solid drugs administration form that comprises at least a culture of microorganism and nutrition associated additives is provided, microorganism and carrier material can need not dry in advance, and/or microorganism and nutrition associated additives are present in each layer, be separated from each other in each case, be introduced at least a passage of its inwall by the solid drugs administration form that will comprise microorganism and nutrition associated additives and form in the packing that agent is embedded into together with at least a absorbent, obtain the sack of the solid drugs administration form that comprises described packing and comprise microorganism.Therefore the present invention also relates to sack, it is included at least a passage formation of inwall agent and is inserted into the packing in small part zone together with at least a absorbent and comprises at least a culture of microorganism and the solid drugs administration form of at least a nutrition associated additives.Nutrition associated additives and microorganism can be preferentially form the pharmaceutical administration forms that unstable product ground is present in bag with the form of mixture each other and exist.Describe in the prior art to having the particularly restriction of multilayer tablet and inapplicable of layer structure.
The vitamin that preferably is present in the solid drugs administration form in the bag according to the present invention is vitamin A (beta-carotene), carotenoid, vitamin D, vitamin C, vitamin E, compound vitamin B and/or vitamin K and quite active related compound is arranged.The compound vitamin B that can preferably exist is folic acid, tetrahydrofolic acid and/or its derivant; (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formoxyl-(6S)-tetrahydrofolic acid, 10-formoxyl-(6R)-tetrahydrofolic acid, 5 particularly; 10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid and/or 5-formamino-(6S)-tetrahydrofolic acid.The amount of vitamin generally depends on the minimum required dosage that various vitamin are recommended, although also can exceed 50% to 300% of average.Preferred range for vitamin C 50 and 300mg between, between 10 to 50mg, be≤1.5mg to be between the 10 μ g to 20mg for vitamin E for vitamin A for compound vitamin B.
The mineral that preferably can be present in the solid drugs administration form in the bag according to the present invention is inorganic or organic sodium, potassium, calcium, magnesium, zinc and/or iron salt, it is suitable for consumption, and preferably with carbonate, bicarbonate, phosphate, hydrophosphate, sulfate, disulfate, chloride, fluoride, citrate and/or lactate.The ratio of mineral, based on the gross weight of solid drugs administration form, preferably by weight from 20 to 40%.The solid administration form preferably comprises silicon, chromium, magnesium, iodine, molybdenum and/or the selenium as trace element.
Being present in the preferably big soyabean bran of dietary fiber, corn bran, Testa Tritici and/or the full paddy of the solid drugs administration form in the bag according to the present invention, particularly preferably is big soyabean bran.The ratio of dietary fiber, based on the gross weight of solid drugs administration form, 2 to 50% weight preferably.
Preferred enzyme or coenzyme are lipase and/or protease or ubiquinone, superoxide dismutase and/or glutathion peroxidase, and it can promote stomach and/or Small Intestine and/or metabolism.Amount that these can be known per se and form known per se are introduced.
The solid drugs administration form that is present in the bag according to the present invention can comprise prebiotic substance in addition, is preferably oligofructose and/or other oligosaccharide.
Preferred plant extract is exsiccant extract, and this paper particularly comprises bioflavonoids, Polyphenols, plant estrogens and/or saponins, such as for example from the extract of Compositae (Echinaceae).
Preferably comprise according to the solid drugs administration form in the bag of the present invention, as protein, soybean protein and/or lactoprotein and/or, as fat, comprise the fat of polyunsaturated fatty acid.
Can comprise traditional adjuvant and additive according to embodiment in addition according to the solid drugs administration form in the bag of the present invention.The selection of adjuvant and/or additive also depends on the food control rules of the country one belongs to that the solid drugs administration form that exists in the bag will use.Adjuvant that uses and/or additive are for example, for tablet, multilayer tablet, dragee, hard capsule, granule, pellets preparation and/or powder, be silicon dioxide, polyvinylpyrrolidone and/or the cellulose powder of starch (for example corn starch), Pulvis Talci, microcrystalline Cellulose, lactose, high degree of dispersion.The other composition that can be used as the existence of binding agent and/or releasing agent is a sugar, such as for example, mannitol, sorbitol, xylitol, glucose, sucrose, fructose, maltose, dextrin, maltodextrin and/or Kaolin and/or cellulose derivative, such as for example, methylcellulose, hydroxypropyl cellulose and/or hydroxypropyl emthylcellulose and/or calcium carbonate, calcium stearate, magnesium stearate and/or tristerin.In addition, the solid drugs administration form in the bag also can comprise dyestuff, spice and/or aromatic, and lubricant, antioxidant and/or stabilizing agent.The content of these base substances depend on the one hand probiotic microorganisms, vitamin, enzyme, dietary fiber, etc. target content, the standard that depends on the machinery/physical property that determines Orally administered form on the other hand, such as for example, hardness, compressibility, size, color and/or shape.
Orally administered form according to the present invention can be used prepared in various methods well known by persons skilled in the art.These methods are known, for example, and H.Sucker, P.Fuchs, P.Speiser, " Pharmaceutische Technologie " (drug technique), Stuttgart1978 or K.H.Bauer, K.H.
C.F ü hrer, " Pharmaceutische Technologie " (drug technique), Stuttgart 1986.This paper introduces in the mode of list of references, and is disclosed some therefore.
Embodiment explains the present invention but not restriction whereby.
Embodiment 1:
3 synusia similar that comprise probiotic bacteria to EP 931 543 A1
Preparation:
3% bacteria preparation (comprises the Jia Shi lactobacillus by weight, bifidobacterium bifidum, bifidobacterium longum), the inulin of 10.5% weight, the calcium phosphate of 8.6% weight, the cellulose of 5.7% weight, adjuvant (the disintegrating agent of 2.3% weight, releasing agent) (ground floor), mineral, trace element, dyestuff, disintegrating agent, releasing agent, cellulose (second layer) and vitamin, trace element, disintegrating agent, the mixture of releasing agent and cellulose (the 3rd layer) (being based on the heavy percent of total sheet in every kind of situation) is suppressed in the 3 laminate machines (rotary tablet machine) of E.Hata in succession, obtains oval 3 synusia of 18mm * 8mm.Next the tablet that obtains provides with film coating (aqueous solution that comprises hydroxypropyl emthylcellulose, hydroxypropyl cellulose and releasing agent), and the clothing layer is corresponding to 11mg/cm
2The sheet surface area be based on 5% of label weight.Obtain 3 synusia of coating, every heavy 1050mg.
Store and check:
In tolerance studies, check the stability of film garment piece.For this reason, the film garment piece is introduced into passage and forms in the packing (packing A) that agent and absorbent together embed inwall or in the polypropylene box (packing B) of band screw lid and be stored in 40 ℃/75%r.h..Behind preset time, the taking-up tablet, the microorganism that is present in every kind of situation is fallen flat band method by counting mensuration by the Koch dilution.The results are shown in table 1 (three batches averages).
Table 1
Embodiment 2
The tablet that comprises antibacterial, vitamin and mineral
Preparation:
It is that 1000mg, diameter are the circular tablet of little drum of 15mm that the compacting in the eccentric tablet machine of Fette E1 of the mixture of the sweeting agent of the acidulant of the releasing agent of the bacteria preparation of the mineral of the vitamin mixtures of the sorbitol of 50% weight, 7.7% weight, 24% weight, 3% weight (comprising Jia Shi lactobacillus, bifidobacterium bifidum, bifidobacterium longum), 6% weight, the dyestuff of 4.5% weight, 2.3% weight, the aromatic of 2.2% weight and 0.06% weight obtains weight.
Similarly store and stability test with embodiment 1.Packing B in this embodiment is the polypropylene box of band screw lid and desiccant bag.The results are shown in the table 2.
Table 2
Embodiment 3
The granule that comprises bacteria preparation
Bacteria preparation is to granulate at Glatt GPCG3 granulator (0.5mm spinning head) with aqueous gelatin solution, and the intake air temperature is 65 ℃, about 45 ℃ of outlet air temperature, hydrojet speed 12g/min.
Embodiment 4
The hard gelatin capsule that comprises bacteria preparation
The mixture of 98% bacteria preparation, 1% ascorbic acid and 1% inulin is packed in the hard gelatin capsule (No. 0 size).
Embodiment 5
The hard gelatin capsule that comprises bacteria preparation
At least the mixture that comprises bacteria preparation (comprising lactobacillus casei, lactococcus lactis, bacillus acidophilus, bifidobacterium bifidum) is packed in the hard gelatin capsule (No. 0).
Similarly store and stability test with embodiment 1.Packing B in this embodiment is organic polymer/aluminum blister pouch.The results are shown in the table 3.
Table 3
Embodiment 6
The hard gelatin capsule that comprises bacteria preparation
The mixture that will comprise bacteria preparation (comprising Lactobacillus rhamnosus GG), microcrystalline Cellulose and magnesium stearate is packed in the hard gelatin capsule (No. 0).
Similarly store and stability test with embodiment 1.The results are shown in the table 4.
Table 4
Embodiment 7
The powder that comprises bacteria preparation
The powder of packing comprises bacteria preparation (containing Lactobacillus rhamnosus GG), maltodextrin, sorbitol and sucrose.
Similarly store and stability test with embodiment 1.The results are shown in the table 5.
Table 5
Claims (10)
1. be used for the stable method that comprises the solid drugs administration form of at least a culture of microorganism, it is characterized in that the solid drugs administration form is introduced at least a passage and forms in the packing of subregion at least that agent and at least a absorbent embed its inwall.
2. according to the method for claim 1, it is characterized in that the solid drugs administration form is tablet, dragee, capsule, grain products, suppository, piller or powder.
3. according to the method for claim 1 and/or 2, it is characterized in that the culture of microorganism that exists is a probiotic microorganisms.
4. according to the method for claim 3, it is characterized in that probiotic microorganisms is lactobacillus, bacillus bifidus or streptococcus, preferred lactobacillus casei, bacillus acidophilus, Lactobacillus reuteri, bifidus, Lactobacillus gasseri, Lactobacillus plantarum, Yue Hanxunshi lactobacillus, lactobacillus rhamnosus, Lactobacillus fermenti, Lactobacillus paracasei, Lactobacillus crispatus, bifidobacterium longum, bifidobacterium bifidum, bifidobacterium longum, newborn bifidus bacillus, short bifidus bacillus, animal bifidus bacillus, bifidobacterium adolescentis, bifidobacterium infantis, streptococcus thermophilus and/or lactococcus lactis.
5. according to the method for claim 1, it is characterized in that packing and comprise by the desiccant as absorbent of Physical Absorption in conjunction with dampness.
6. according to the method for claim 5, it is characterized in that desiccant is molecular sieve or silica gel.
7. comprise according to one in the claim 1,5 and 6 or multinomial packing with according to one in the claim 1 to 4 or the multinomial sack that comprises the solid drugs administration form of at least a culture of microorganism.
8. according to the sack of claim 7, it is characterized in that the solid drugs administration form that exists is used for Orally administered in packing.
9. according to the sack of claim 7 and/or 8, it is characterized in that the solid drugs administration form that exists comprises 10 in packing
3To 10
12, preferred 10
5To 10
11And preferred especially 10
7To 10
10Individual microorganism.
10. according to or multinomial sack of claim 7 to 9, it is characterized in that the pharmaceutical administration forms that exists also comprises the nutrition associated additives in packing, preferred vitamin, mineral, trace element, dietary fiber, enzyme, plant extract, protein, sugar and/or fatty.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05021254.7 | 2005-09-29 | ||
EP05021254 | 2005-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101272770A true CN101272770A (en) | 2008-09-24 |
Family
ID=37450762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800355746A Pending CN101272770A (en) | 2005-09-29 | 2006-08-30 | Method for stabilising pharmaceutical administration forms that contain micro-organisms |
Country Status (17)
Country | Link |
---|---|
US (1) | US9072784B2 (en) |
EP (1) | EP1928426B1 (en) |
JP (1) | JP2009509983A (en) |
KR (1) | KR20080059605A (en) |
CN (1) | CN101272770A (en) |
AU (1) | AU2006296797B8 (en) |
BR (1) | BRPI0616429B1 (en) |
CA (1) | CA2623968C (en) |
CY (1) | CY1115838T1 (en) |
DK (1) | DK1928426T3 (en) |
EA (1) | EA014825B1 (en) |
ES (1) | ES2526094T3 (en) |
PL (1) | PL1928426T3 (en) |
PT (1) | PT1928426E (en) |
SI (1) | SI1928426T1 (en) |
WO (1) | WO2007036278A2 (en) |
ZA (1) | ZA200803666B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101865595A (en) * | 2009-04-14 | 2010-10-20 | 瑞阳制药有限公司 | New application of molecular sieve and drying method of solid drugs |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080095752A1 (en) * | 2006-10-20 | 2008-04-24 | Win-Chin Chiang | Method for extending the shelf-life of powdered nutritional formulations which contain viable probiotics |
EP2109570A1 (en) * | 2007-01-20 | 2009-10-21 | Merck Patent GmbH | Packaging containing soft capsules |
CN102124097B (en) * | 2008-08-28 | 2013-11-06 | 科.汉森有限公司 | Bacterial composition |
US20110070334A1 (en) * | 2009-09-20 | 2011-03-24 | Nagendra Rangavajla | Probiotic Stabilization |
US9011909B2 (en) | 2010-09-03 | 2015-04-21 | Wisconsin Pharmacal Company, Llc | Prebiotic suppositories |
JP5940869B2 (en) * | 2012-04-20 | 2016-06-29 | 日清ファルマ株式会社 | Intestinal environment-improved dry-coated tablets and hard capsules |
JP6243276B2 (en) * | 2014-03-31 | 2017-12-06 | 株式会社ファンケル | Hard capsule formulation with improved acid resistance of the drug substance |
MX2016016773A (en) | 2014-07-01 | 2017-06-30 | Probi Usa Inc | Bi-layer dual release probiotic tablets. |
CN104988084B (en) * | 2015-02-28 | 2017-10-20 | 江南大学 | Lactobacillus gasseri of one plant of production synanthrin and application thereof |
ITUB20152151A1 (en) * | 2015-07-14 | 2017-01-14 | Ergon Srl | HIGH-CONCENTRATED COMPRESSION OF LATEX FERMENTS |
EP3556226B1 (en) * | 2018-04-20 | 2021-01-20 | Raab Vitalfood GmbH | Complex synbiotic for establishing healthy intestinal flora |
EP3955899A1 (en) | 2019-04-15 | 2022-02-23 | Institut D'Investigacions Biomèdiques August Pi I Sunyer - IDIBAPS | Long-term stable live fecal microbiota composition |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60227664A (en) * | 1984-04-24 | 1985-11-12 | Mishima Shokuhin Kk | Sprinkling flour containing lactobacillus bifidus and preparation thereof |
JPS61103445A (en) * | 1984-10-24 | 1986-05-21 | 三菱瓦斯化学株式会社 | Method for preserving drug |
JPH07322824A (en) * | 1994-05-30 | 1995-12-12 | Snow Brand Food Co Ltd | Powdery mix for frozen dessert exhibiting yogurt-like taste and flavor |
US6316520B1 (en) * | 1995-04-19 | 2001-11-13 | Capitol Specialty Plastics, Inc. | Monolithic polymer composition having a releasing material |
US5911937A (en) | 1995-04-19 | 1999-06-15 | Capitol Specialty Plastics, Inc. | Desiccant entrained polymer |
US6279736B1 (en) * | 1995-04-19 | 2001-08-28 | Capitol Specialty Plastics, Inc. | Barrier pack having an absorbing agent applied to the interior of the pack |
PL322946A1 (en) * | 1995-04-19 | 1998-03-02 | Capitol Vial Inc | Dessicating material enclosed in a closed container |
US6486231B1 (en) * | 1995-04-19 | 2002-11-26 | Csp Technologies, Inc. | Co-continuous interconnecting channel morphology composition |
GB9705456D0 (en) * | 1997-03-17 | 1997-05-07 | Ucb Sa | Yoghurt production process |
SE9703669D0 (en) * | 1997-10-08 | 1997-10-08 | Moelnlycke Ab | Articles and preparation comprising lactic acid bacteria |
PT931543E (en) * | 1997-12-19 | 2002-09-30 | Merck Patent Gmbh | TABLETS OF SEVERAL LAYERS CONTAINING PROBIOTIC MICROORGANISMS AS FOR EXAMPLE LACTOBACILUS OR BIFIDOBACTERIAS |
SE9902207L (en) * | 1999-06-11 | 2000-12-12 | Sca Hygiene Prod Ab | Use of moisture-tight packaging for absorbent articles containing moisture-sensitive additives |
EP1072258A1 (en) * | 1999-07-28 | 2001-01-31 | Greither, Peter | Capsule for the release of bacteria, containing lyophilised bacteria and a method for the production thereof |
SE0104199L (en) * | 2001-12-13 | 2003-06-14 | Sca Hygiene Prod Ab | New product |
GB0330009D0 (en) * | 2003-12-24 | 2004-01-28 | Ferrosan As | Probiotic tablet formulations |
-
2006
- 2006-08-30 PL PL06777115T patent/PL1928426T3/en unknown
- 2006-08-30 AU AU2006296797A patent/AU2006296797B8/en active Active
- 2006-08-30 EP EP06777115.4A patent/EP1928426B1/en active Active
- 2006-08-30 US US12/088,479 patent/US9072784B2/en active Active
- 2006-08-30 DK DK06777115.4T patent/DK1928426T3/en active
- 2006-08-30 JP JP2008532619A patent/JP2009509983A/en active Pending
- 2006-08-30 SI SI200631868T patent/SI1928426T1/en unknown
- 2006-08-30 KR KR1020087010125A patent/KR20080059605A/en not_active Application Discontinuation
- 2006-08-30 EA EA200800698A patent/EA014825B1/en not_active IP Right Cessation
- 2006-08-30 CN CNA2006800355746A patent/CN101272770A/en active Pending
- 2006-08-30 WO PCT/EP2006/008468 patent/WO2007036278A2/en active Application Filing
- 2006-08-30 BR BRPI0616429-3A patent/BRPI0616429B1/en active IP Right Grant
- 2006-08-30 ES ES06777115.4T patent/ES2526094T3/en active Active
- 2006-08-30 CA CA2623968A patent/CA2623968C/en active Active
- 2006-08-30 PT PT67771154T patent/PT1928426E/en unknown
-
2008
- 2008-04-25 ZA ZA200803666A patent/ZA200803666B/en unknown
-
2014
- 2014-12-18 CY CY20141101065T patent/CY1115838T1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101865595A (en) * | 2009-04-14 | 2010-10-20 | 瑞阳制药有限公司 | New application of molecular sieve and drying method of solid drugs |
Also Published As
Publication number | Publication date |
---|---|
AU2006296797B2 (en) | 2012-05-24 |
PT1928426E (en) | 2014-12-02 |
BRPI0616429B1 (en) | 2021-10-13 |
WO2007036278A8 (en) | 2007-06-21 |
EA014825B1 (en) | 2011-02-28 |
CA2623968A1 (en) | 2007-04-05 |
PL1928426T3 (en) | 2015-04-30 |
WO2007036278A3 (en) | 2007-08-16 |
DK1928426T3 (en) | 2014-12-01 |
CY1115838T1 (en) | 2017-01-25 |
KR20080059605A (en) | 2008-06-30 |
AU2006296797A1 (en) | 2007-04-05 |
BRPI0616429A2 (en) | 2011-06-21 |
EP1928426A2 (en) | 2008-06-11 |
JP2009509983A (en) | 2009-03-12 |
WO2007036278A2 (en) | 2007-04-05 |
US20080219961A1 (en) | 2008-09-11 |
SI1928426T1 (en) | 2015-01-30 |
US9072784B2 (en) | 2015-07-07 |
ES2526094T3 (en) | 2015-01-05 |
EP1928426B1 (en) | 2014-10-01 |
AU2006296797B8 (en) | 2012-06-28 |
ZA200803666B (en) | 2009-02-25 |
EA200800698A1 (en) | 2008-12-30 |
CA2623968C (en) | 2014-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101272770A (en) | Method for stabilising pharmaceutical administration forms that contain micro-organisms | |
JP5224606B2 (en) | Probiotic oral dosage form | |
RU2731158C2 (en) | Stable dry compositions with or without low content of sugars | |
JP3844597B2 (en) | Multilayer tablet | |
CN1956724B (en) | Oral form of administration containing probiotic bacteria | |
AU770792B2 (en) | Oral form of administration containing probiotic micro-organisms | |
US20110014278A1 (en) | Compositions Comprising Dehydrated Micro-Organisms, Method for Preparing Same, and Uses Thereof | |
US11337926B2 (en) | Colon-targeted composition of biological active component and application thereof | |
WO2010114864A1 (en) | Probiotic oral dosage forms | |
CN107998152A (en) | A kind of probiotics tablets of colon release | |
NZ742496B2 (en) | Stable dry compositions having no or little sugars |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20080924 |